Chair of Experimental Bioinformatics, TUM School of Life Sciences, Technical University of Munich, München, Germany.
Institute of Virology, TUM School of Medicine, Technical University of Munich, München, Germany.
Nat Commun. 2020 Jul 14;11(1):3518. doi: 10.1038/s41467-020-17189-2.
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Various studies exist about the molecular mechanisms of viral infection. However, such information is spread across many publications and it is very time-consuming to integrate, and exploit. We develop CoVex, an interactive online platform for SARS-CoV-2 host interactome exploration and drug (target) identification. CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-target interactions. It allows visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drug candidates. Thus, CoVex is a resource to understand molecular mechanisms of pathogenicity and to prioritize candidate therapeutics. We investigate recent hypotheses on a systems biology level to explore mechanistic virus life cycle drivers, and to extract drug repurposing candidates. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms. It is available at https://exbio.wzw.tum.de/covex/.
新型冠状病毒肺炎(COVID-19)是由 SARS-CoV-2 病毒引起的传染病。关于病毒感染的分子机制有很多研究。但是,这些信息散布在许多出版物中,整合和利用非常耗时。我们开发了 CoVex,这是一个用于 SARS-CoV-2 宿主相互作用组探索和药物(靶标)鉴定的交互式在线平台。CoVex 整合了病毒-人类蛋白质相互作用、人类蛋白质-蛋白质相互作用和药物-靶标相互作用。它允许对病毒-宿主相互作用组进行可视化探索,并实现基于网络的药物候选物预测的系统医学算法。因此,CoVex 是理解发病机制和确定治疗候选药物优先级的资源。我们在系统生物学水平上研究最近的假说,以探索机制病毒生命周期驱动因素,并提取药物再利用候选物。CoVex 通过让科学界直接访问网络医学算法,使 COVID-19 药物研究具有系统医学的准备。它可以在 https://exbio.wzw.tum.de/covex/ 上获得。